Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs Vorinostat (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms NSCLC
  • Most Recent Events

    • 23 Jan 2017 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017.
    • 23 Jan 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
    • 23 Jan 2017 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top